'Akcea therapeutics' presentation slideshows

Familial Chylomicronemia Syndrome Treatment Market New Business Opportunities and Investment Research Report 2018-2026

Familial Chylomicronemia Syndrome is a genetic condition characterized by an inability of the body to digest fats mainly triglyceride. In Familial Chylomicronemia Syndrome, the lipoprotein lipase (LPS) is not functional, which is the enzyme that breaks down chylomicrons in the blood. Healthcare providers can clinically diagnosed FCS by looking for acute pancreatitis, abdominal pain, uncontrolled diabetes, excess alcohol intake and hypertriglyceridemia. Click To Read More On Familial Chylomicronemia Syndrome Treatment Market

45 views • 3 slides